Diagnostic value of thrombocytosis and high CA 125 level in women with adnexal masses

Aim: The aim of this study was to determine the diagnostic value of thrombocytosis and high CA 125 levels in women with benign and malign adnexal masses. Thrombocytosis (platelet counts > 400 x 10(9)/l) has been identified as a poor prognostic factor in many cancers including certain gynecologic malignant tumors such as endometrial, cervical, and ovarian cancers. Methods: Medical charts of 180 patients with adnexal masses were retrospectively reviewed and analyzed for the association of preoperative thrombocytosis and high CA 125 level with other clinical prognostic factors. Results: Of the 180 participants, 68 (68% of malignant adnexal masses) had thrombocytosis and 74 patients (74% of malignant adnexal masses) had elevated CA 125 levels. The patients with preoperative thrombocytosis were found to have greater elevations of CA 125 levels, more advanced stage disease, and higher grade tumors. Conclusion: Presence of thrombocytosis and high CA 125 alone and in combination may be used as a prognostic factor in the management of women with adnexal masses since they are already used as clinical tests for several purposes.

Thrombocytosis; CA125; Adnexal masses

[1] Hoffman M.S.: “Differential diagnosis of the adnexal mass”. In: UpToDate, Falk S.J. (ed.), UpToDate, Waltham, MA, 2011.

[2] Teng N., Simons E.J.: “Adnexal tumors. Available at: http://emedicine.medscape.com/article/258044-overview”.

[3] Pedersen L.M., Milman N.: “Diagnostic significance of platelet count and other blood analyses in patients with lung cancer”. Oncol. Rep., 2003, 10, 213.

[4] O’Keefe S.C., Marshall F.F., Issa M.M., Harmon M.P., Petros J.A.: “Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy”. J. Urol., 2002, 168, 1378.

[5] Costantini V., Zacharski L.R., Moritz T.E., Edwards R.L.: “The platelet count in carcinoma of the lung and colon”. Thromb. Haemost., 1990, 64, 501.

[6] Gücer F., Moser F., Tamussino K., Reich O., Haas J., Arikan G. et al.: “Thrombocytosis as a prognostic factor in endometrial carcinoma”. Gynecol. Oncol., 1998, 70, 210.

[7] Lerner D.L., Walsh C.S., Cass I., Karlan B.Y., Li A.J.: “The prognostic significance of thrombocytosis in uterine papillary serous carcinomas”. Gynecol. Oncol., 2007, 104, 91.

[8] Hernandez E., Donohue K.A., Anderson L.L., Heller P.B., Stehman F.B.: “The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2000, 78, 137.

[9] Zeimet A.G., Marth C., Müller-Holzner E., Daxenbichler G., Dapunt O.: “Significance of thrombocytosis in patients with epithelial ovarian cancer”. Am. J. Obstet. Gynecol., 1994, 170, 549.

[10] Menczer J., Schejter E., Geva D., Ginath S., Zakut H.: “Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival”. Eur. J. Gynaecol. Oncol., 1998, 19, 82.

[11] Chalas E., Welshinger M., Engellener W., Chumas J., Barbieri R., Mann W.J.: “The clinical significance of thrombocytosis in women presenting with a pelvic mass”. Am. J. Obstet. Gynecol., 1992, 166, 974.

[12] Gastl G., Plante M., Finstad C.L., Wong G.Y., Federici M.G., Bander N.H., Rubin S.C.: “High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer”. Br. J. Haematol., 1993, 83, 433.

[13] Kerpsack J.T., Finan M.A.: “Thrombocytosis as a predictor of malignancy in women with a pelvic mass”. J. Reprod. Med., 2000, 45, 929.

[14] Kenemans P., Yedema C.A., Bon G.G., von Mensdorff-Pouilly S.: “CA 125 in gynecological pathology - a review”. Eur. J. Obstet. Gynecol. Reprod. Biol., 1993, 49, 115.

[15] Gadducci A., Cosio S., Carpi A., Nicolini A., Genazzani A.R.: “Serum tumor markers in the management of ovarian, endometrial and cervical cancer”. Biomed. Pharmacother, 2004, 58, 24.

[16] Van Calster B., Valentin L., Van Holsbeke C., Zhang J., Jurkovic D., Lissoni A.A. et al.: “A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study”. Cancer Epidemiol. Biomarkers Prev., 2011, 20, 2420.

[17] Liu J.H., Zanotti K.M.: “Management of the adnexal mass”. Obstet. Gynecol., 2011, 117, 1413.

[18] Nolen B.M., Lokshin A.E.: “Protein biomarkers of ovarian cancer: the forest and the trees”. Future Oncol., 2012, 8, 55.

[19] Verheijen R.H., Cibula D., Zola P., Reed N.: “Cancer Antigen 125: Lost to Follow-Up?: A European Society of Gynaecological”. Oncol. Int. J. Gynecol. Cancer, 2012, 22, 170.

[20] Mury D., Woelber L., Jung S., Eulenburg C., Choschzick M., Witzel I. et al.: “Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer”. J. Cancer Res. Clin. Oncol., 2011, Vol. 137, 1131.

[21] Li A.J., Madden A.C., Cass I., Leuchter R.S., Lagasse L.D., Karlan B.Y.: “The prognostic significance of thrombocytosis in epithelial ovarian carcinoma”. Gynecol. Oncol., 2004, 92, 211.

[22] Lerner D.L., Walsh C.S., Cass I., Karlan B.Y., Li A.J.: “The prognostic significance of thrombocytosis in uterine papillary serous carcinomas”. Gynecol. Oncol., 2007, 104, 91.